Loading
A phase 2 trial of Durvalumab, Olaparib, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) is a phase 2 interventional study registered as NCT03775486 by AstraZeneca, with 401 participants enrolled, started 2018-12-21 and due to reach its primary completion in 2021-01-11. Interventions recorded: Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin. Conditions listed: Non-small Cell Lung Cancer NSCLC. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pemetrexed, Durvalumab, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
Shares PARP inhibitors, Olaparib, Durvalumab, AstraZeneca.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
Shares PARP inhibitors, Olaparib, Durvalumab, AstraZeneca.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares PARP inhibitors, Olaparib, Durvalumab, AstraZeneca.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/